Generic smear campaign earns Merck French fine
This article was originally published in Scrip
Executive Summary
The French competition authority has fined Merck & Co's Schering-Plough business €15.3m for attempting to block from the market a generic version of its opioid addiction drug Subutex (buprenorphine).